FDA WARNING_LETTER - Marks Marine Pharmacy - August 23, 2012
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On August 23, 2012, the FDA issued a Warning Letter to Mark's Marine Pharmacy in Vancouver, B.C., for illegally promoting and selling clobazam, an unapproved and misbranded new drug, to U.S. patients and healthcare professionals. The pharmacy violated sections 502(f) and 505(a) of the FD&C Act [21 U.S.C. §§ 352(f) and 355(a)], and prohibited acts under sections 301(a) and 301(d) [21 U.S.C. §§ 331(a) and 331(d)].
The FDA stated that clobazam is an unapproved new drug because no approved application under section 505 of the FD&C Act exists for any clobazam product other than Lundbeck’s ONFI Tablets, approved October 21, 2011. Mark's Marine Pharmacy sent letters to U.S. patients and physicians advertising their ability to supply Canadian clobazam for non-Lennox-Gastaut Syndrome patients, despite ONFI's specific approval for that condition.
Furthermore, the clobazam product was deemed misbranded under section 502(f)(1) [21 U.S.C. § 352(f)(
ID · d745e957-3dd7-43a0-b344-35d97d85c8d0
Full citation text and observation details available on the Dashboard.